Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70

Benzinga · 11/04 17:20
Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.